Search

Objectives: 1) to find out the distribution of prostate cancer by risk of progression; 2) to determine the cause-specific survival by risk of progression in prostate cancer; 3) to identify the factors associated with the risk of dying from this cancer.Methods: Incident prostate cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: invasive cases with code C61.9 and any histology. Cases identified exclusively through death certificate were excluded. We collected: age; date and method of diagnosis; date of follow-up or death; T, N, M and stage according to the TNM 7th edition; Gleason score; PSA; histology according to the ICD-O 3rd edition 6 ; comorbidities and treatments. We calculated risk in 4 categories: low, medium, high and very high. End point of follow-up was 31 December 2014. Multiple imputation (MI) was performed to estimate cases with unknown risk of progression. Survival analysis was performed using the actuarial and Kaplan-Meier methods, as well as the Cox regression model.Results: We identified 2921 cases. After MI, 9.5% had low risk, 24.9% medium risk, 42.7% high risk and 22.9% very high risk. Five years after diagnosis, survival after MI was 89% globally, that being 100% for low risk cases, 96% for medium risk, 93% for high risk and 69% for very high risk. Cases with histology other than adenocarcinoma, with high and, especially, very high risk of progression, as well as with systemic, mixed and observation/unspecified treatments have worse prognosis. Treatment showed a strong relationship with age and life expectancy.Conclusions: Risk of progression and treatment were the main variables associated to survival in prostate cancer.

Background: Information about survival by stage in bladder cancer is scarce. Objectives: 1) to find out the distribution of bladder and urinary tract cancers by stage; 2) to determine cancer-specific survival by stage of bladder and urinary tract cancers; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.Methods: Incident bladder and urinary tract cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with codes C65–C68 (ICD-O 3) with any behaviour. DCO cases were excluded. We collected: sex; age; date and method of diagnosis; histology (ICD-O 3); T, N, M and stage at the time of diagnosis; and date of follow-up or death. End of follow up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Actuarial and Kaplan-Meier methods and Cox regression models were used.Results: 2060 cases were identified. 15% were women and 65.2% were 65 years or older. 3.7% had no stage (benign or undetermined behaviour) and 12.5% had unknown stage. After MI, 35.7% were in stage Ta (non-invasive papillary carcinoma), 3.1% in stage Tis (carcinoma in situ), 33.3% in stage I, 11.9 % in Stage II, 4.7% in stage III, and 11.1% in stage IV. Survival was 73% at 5 years. Survival by stage: 98% at stage Ta, 88% at stage Tis, 84% at stage I, 44% at stage II, 33% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage were associated with survival.Conclusion: Bladder and urinary tract cancers survival vary greatly with stage. The percentage of non-invasive cancers was high. Stage, age and histology are associated to survival, but sex has no association.

Background: 1) to find out the distribution of bladder and urinary tract cancers by stage; 2) to determine cause-specific survival by stage of bladder and urinary tract cancers; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.Methods: Incident bladder and urinary tract cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with codes C65–C68 according to the ICD-O 3rd edition with any behaviour. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.Results: 2060 cases were identified. 15% were women and 65.2% were 65 years or older. 93.6% consisted of bladder and other urinary tracts. 55.7% were papillary transitional neoplasia, 37.7% solid transitional, 0.6% microcytic, and the rest of other histology. 3.7% had no stage (benign or undetermined behaviour) and 12.5% had unknown stage. After MI, 35.7% were in stage 0a (non-invasive papillary carcinoma), 3.1% in stage 0is (carcinoma in situ), 33.3% in stage I, 11.9 % in Stage II, 4.7% in stage III, and 11.1% in stage IV. Survival was 73% at 5 years. Survival by stage: 98% at stage 0a, 88% at stage 0is, 84% at stage I, 44% at stage II, 33% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage were associated with survival.Conclusion: Bladder and urinary tract cancers survival vary greatly with stage, among both non-invasive and invasive cases.